Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of histologically proven lymphoproliferative disease specified as Hodgkin's disease, non-Hodgkin's lymphoma (NHL) or multiple myeloma~* Indication of high-dose therapy and autologous peripheral blood stem cell transplantation~* Availability of a sufficient amount of blood stem cells (CD34+ cells \>= 2.0 x 106/kg)~* Age between 18 and 70 years~* High-dose therapy with one of the following high-dose regimes: Melphalan 140 mg/m2 or 200 mg/m2, BEAM, BEAC, BUCY or CBV (the last permitted according to amendment 2, see Section 9.8.1)~* Patient's written consent to participation in this trial~Exclusion Criteria:~* Previous high-dose therapy and blood stem cell transplantation except for melphalan 140 mg/m2 or 200 mg/m2 in patients with multiple myeloma who did not participate in the cytocapacity test previously (according to amendment 2, see Section 9.8.1).~* Known intolerance to lenograstim~* Out-patient therapy following high-dose therapy and blood stem cell transplantation~* Myocardial infarction \< 6 months prior to inclusion into the study~* Cardiac arrhythmias Lown IV b~* Clinically manifest cardiac insufficiency (\> NYHA II)~* Renal insufficiency with serum creatinine \> 2 mg%~* Hepatic diseases with elevated levels of transaminases and bilirubin greater than 3-fold above normal~* Severe infections (HIV, Hepatitis B/C)~* Severe psychiatric diseases~* Non-curative treatment of other malignoma within the past 5 years~* Pregnant women or women breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A: lenograstim (Type: EXPERIMENTAL): total group

Based on this trial design, predict the completion outcome and termination type (if applicable).